Abstract: OBJECTIVE To explore the influence of antiviral therapy on liver function and pregnancy outcomes of the hepatitis B surface antigen（HBsAg）-positive pregnant women as well as hepatitis B virus（HBV） infection in infants. METHODS A total of 87 HBV infection pregnant women complicated with transaminase abnormalities who were treated in the People’s Hospital in Banan District from Jun 2016 to Jun 2020 were enrolled in the study and divided into the antiviral therapy group with 31 cases and the no antiviral therapy group with 56 cases. The liver function indexes of the two groups of pregnant women were detected, and the pregnancy outcomes and incidence of HBV infection in infants were statistically analyzed. RESULTS The levels of alanine aminotransferase（ALT）, aspartate aminotransferase（AST） and total bile acid（TBA） of the two groups of patients were significantly lower after the treatment for 1 month or before deliver than before the treatment（P＜0.05）; there were no significant differences in the levels of ALT, AST and TBA between the two groups before the treatment and before delivery, however, the levels of above indexes of the antiviral therapy group were significantly lower than those of the no antiviral therapy group after the treatment for 1 month（P＜0.05）. The number of HBV-DNA copies and HBeAg-positive cases was significantly less in the antiviral therapy group than in the no antiviral therapy group before delivery（P＜0.05）. The incidence rates of gestational complications, premature delivery and postpartum hemorrhage of the antiviral therapy group were respectively 9.68%, 0% and 3.22%,significantly lower than those of the no antiviral therapy group（P＜0.05）. The positive rate of HBV-DNA or HBsAg and immune failure rate of infants of the antiviral therapy group were respectively 3.22% and 0% at their birth, significantly lower than those of the no antiviral therapy group（P＜0.05）. CONCLUSION The antiviral therapy can improve the liver function and adverse pregnancy outcomes of the HBV infection pregnant women complicated with transaminase abnormalities and reduce the risk of HBV infection in neonates, and it is safe.